Elective neck dissection or sentinel lymph node biopsy in early stage oral cavity cancer patients: The dutch experience

Inne J. Den Toom, Koos Boeve, Daphne Lobeek, Elisabeth Bloemena, Maarten L. Donswijk, Bart de Keizer, W. Martin C. Klop, C. René Leemans, Stefan M. Willems, Robert P. Takes, Max J.H. Witjes, Remco de Bree*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Sentinel lymph node biopsy (SLNB) has been introduced as a diagnostic staging modality for detection of occult metastases in patients with early stage oral cancer. Comparisons regarding accuracy to the routinely used elective neck dissection (END) are lacking in literature. Methods: A retrospective, multicenter cohort study included 390 patients staged by END and 488 by SLNB. Results: The overall sensitivity (84% vs. 81%, p = 0.612) and negative predictive value (NPV) (93%, p = 1.000) were comparable between END and SLNB patients. The END cohort contained more pT2 tumours (51%) compared to the SLNB cohort (23%) (p < 0.001). No differences were found for sensitivity and NPV between SLNB and END divided by pT stage. In floor-of-mouth (FOM) tumours, SLNB had a lower sensitivity (63% vs. 92%, p = 0.006) and NPV (90% vs. 97%, p = 0.057) compared to END. Higher disease-specific survival (DSS) rates were found for pT1 SLNB patients compared to pT1 END patients (96% vs. 90%, p = 0.048). Conclusion: In the absence of randomized clinical trials, this study provides the highest available evidence that, in oral cancer, SLNB is as accurate as END in detecting occult lymph node metastases, except for floor-of-mouth tumours.

Original languageEnglish
Article number1783
Pages (from-to)1-13
Number of pages13
JournalCancers
Volume12
Issue number7
DOIs
Publication statusPublished - Jul 2020

Cite this

Den Toom, I. J., Boeve, K., Lobeek, D., Bloemena, E., Donswijk, M. L., de Keizer, B., ... de Bree, R. (2020). Elective neck dissection or sentinel lymph node biopsy in early stage oral cavity cancer patients: The dutch experience. Cancers, 12(7), 1-13. [1783]. https://doi.org/10.3390/cancers12071783